Medizin
Refine
Year of publication
- 2017 (347) (remove)
Document Type
- Article (319)
- Part of Periodical (11)
- Doctoral Thesis (9)
- Book (3)
- Contribution to a Periodical (3)
- Preprint (1)
- Report (1)
Language
- English (311)
- German (32)
- Multiple languages (3)
- Spanish (1)
Has Fulltext
- yes (347)
Is part of the Bibliography
- no (347)
Keywords
- glioblastoma (8)
- Inflammation (4)
- Neuroscience (4)
- multiple sclerosis (4)
- Apoptosis (3)
- Denosumab (3)
- Kinematic analysis (3)
- Mechanisms of disease (3)
- Mitochondria (3)
- Molecular biology (3)
Institute
Sex differences in the relationship between conduct disorder and cortical structure in adolescents
(2017)
Objective: Previous studies have reported reduced cortical thickness and surface area and altered gyrification in frontal and temporal regions in adolescents with conduct disorder (CD). Although there is evidence that the clinical phenotype of CD differs between males and females, no studies have examined whether such sex differences extend to cortical and subcortical structure.
Method: As part of a European multisite study (FemNAT-CD), structural magnetic resonance imaging (MRI) data were collected from 48 female and 48 male participants with CD and from 104 sex-, age-, and pubertal-status−matched controls (14–18 years of age). Data were analyzed using surface-based morphometry, testing for effects of sex, diagnosis, and sex-by-diagnosis interactions, while controlling for age, IQ, scan site, and total gray matter volume.
Results: CD was associated with cortical thinning and higher gyrification in ventromedial prefrontal cortex in both sexes. Males with CD showed lower, and females with CD showed higher, supramarginal gyrus cortical thickness compared with controls. Relative to controls, males with CD showed higher gyrification and surface area in superior frontal gyrus, whereas the opposite pattern was seen in females. There were no effects of diagnosis or sex-by-diagnosis interactions on subcortical volumes. Results are discussed with regard to attention-deficit/hyperactivity disorder, depression, and substance abuse comorbidity, medication use, handedness, and CD age of onset.
Conclusion: We found both similarities and differences between males and females in CD–cortical structure associations. This initial evidence that the pathophysiological basis of CD may be partly sex-specific highlights the need to consider sex in future neuroimaging studies and suggests that males and females may require different treatments.
Correlation of lumbar lateral recess stenosis in magnetic resonance imaging and clinical symptoms
(2017)
Aim: To assess the correlation of lateral recess stenosis (LRS) of lumbar segments L4/5 and L5/S1 and the Oswestry Disability Index (ODI).
Methods: Nine hundred and twenty-seven patients with history of low back pain were included in this uncontrolled study. On magnetic resonance images (MRI) the lateral recesses (LR) at lumbar levels L4/5 and L5/S1 were evaluated and each nerve root was classified into a 4-point grading scale (Grade 0-3) as normal, not deviated, deviated or compressed. Patient symptoms and disability were assessed using ODI. The Spearman’s rank correlation coefficient was used for statistical analysis (P < 0.05).
Results: Approximately half of the LR revealed stenosis (grade 1-3; 52% at level L4/5 and 42% at level L5/S1) with 2.2% and 1.9% respectively reveal a nerve root compression. The ODI score ranged from 0%-91.11% with an arithmetic mean of 34.06% ± 16.89%. We observed a very weak statistically significant positive correlation between ODI and LRS at lumbar levels L4/5 and L5/S1, each bilaterally (L4/5 left: rho < 0.105, P < 0.01; L4/5 right: rho < 0.111, P < 0.01; L5/S1 left: rho 0.128, P < 0.01; L5/S1 right: rho < 0.157, P < 0.001).
Conclusion: Although MRI is the standard imaging tool for diagnosing lumbar spinal stenosis, this study showed only a weak correlation of LRS on MRI and clinical findings. This can be attributed to a number of reasons outlined in this study, underlining that imaging findings alone are not sufficient to establish a reliable diagnosis for patients with LRS.
Synthetische Cannabinoide sind strukturell variable Substanzen, die an die gleichen CB1- und CB2-Rezeptoren binden wie ∆9-THC und bei Konsumenten vergleichbare Symptome auslösen. Die psychoaktiven Substanzen werden Kräutermischungen beigemengt und gelten unter Konsumenten vermeintlich als ungefährlich. Aufgrund erhöhter Bindungsaffinitäten zu den Cannabinoidrezeptoren sind viele synthetische Cannabinoide potenter als ∆9-THC und lösen daher stärkere Symptome aus als der Konsum von ∆9-THC. Der Konsum von synthetischen Cannabinoiden führt zu zentraler Sedierung und Beeinträchtigungen in der Feinmotorik; dies ist nicht mit dem sicheren Führen eines Fahrzeugs kompatibel. Durch die strukturelle Varianz von synthetischen Cannabinoiden und ein stetig wechselndes Spektrum aktuell auf dem Drogenmarkt erhältlicher Substanzen ist der generelle Nachweis des Konsums von synthetischen Cannabinoiden limitiert. Bislang sind synthetische Cannabinoide in Blut oder Urin nur bei bekannter Struktur und vorhandenen Referenzmaterialien mit Sicherheit nachweisbar. Studien zur Prävalenz von synthetischen Cannabinoiden sind rar und basieren häufig auf Umfragen, da auf Probenanalysen basierende Studien meist nicht alle aktuellen synthetischen Cannabinoiden erfassen. In der vorliegenden Arbeit wurde die Prävalenz von synthetischen Cannabinoiden unter Fällen aus Verkehrs- und Kriminaldelikten des Jahres 2010 in Hessen bestimmt, um zu zeigen wie häufig synthetische Cannabinoide in forensischen Analysen unentdeckt bleiben. Die analytische Methode wurde entwickelt sowie validiert und war für alle 31 synthetischen Cannabinoide, die bis 2011 auf dem Drogenmarkt erhältlich waren, sensitiv. Eine repräsentative Stichprobe bestehen aus 20% aller Blutproben (422 aus 2201) des Jahres 2010 wurde nachuntersucht. Weitere Auswertungen wurden auf Basis von Fallakten durchgeführt. Unter den analysierten Blutproben enthielten 12 Proben synthetische Cannabinoide, woraus für das Jahr 2010 eine Prävalenz von synthetischen Cannabinoiden unter Fällen aus Verkehrs- und Kriminaldelikten von 2,8% ermittelt wurde. Das am häufigsten detektierte synthetische Cannabinoid war JWH-122. Die Konzentrationen lagen überwiegend im niedrigen Bereich (unter 1 ng/ml bis 3 ng/ml). In einem Fall wurde eine vergleichsweise hohe Konzentration des JWH-122 mit circa 73 ng/ml gemessen, wobei neben Apathie keine weiteren Symptome dokumentiert wurden. Alle Konsumenten waren männlich; das Alter lag in 11 Fällen zwischen 18 und 38 Jahren (median 22 Jahre) und die Konsumenten waren Verdächtige von Verkehrsdelikten. Eine weitere positiv getestete Blutprobe stammte aus einem Kriminaldelikt; der Verdächtige war 46 Jahre alt. Die Auswertung der Konsummuster zeigte in 10 von 12 Fällen (83,3%) einen Mischkonsum. Nur in zwei Fällen lag ausschließlicher Konsum von synthetischen Cannabinoiden vor. Die Kombination von synthetischen Cannabinoiden mit ∆9-THC oder Alkohol war mit je vier Fällen häufig. In sechs Fällen wurde eine Vielfalt anderer psychoaktiver Drogen oder Medikamente in den Blutproben nachgewiesen. Die dokumentierten Ausfallserscheinungen waren meist moderat und ließen sich durch die Effekte von Cannabinoiden, Alkohol oder anderen gefundenen Drogen oder Medikamenten erklären. Im Fall eines Konsumenten hat sich nach den Angaben in ärztlichen und polizeilichen Berichten durch den nachgewiesenen Konsum von synthetischen Cannabinoiden eine vorbestehende Psychose verschlimmert. Fazit: Durch die geringe Prävalenz synthetischer Cannabinoide, fehlende routinemäßige Erfassbarkeit sowie Häufigkeit des Mischkonsums müssen Träger von rechtsmedizinischen Instituten in Ausstattung und Personal investieren, um den modernen Ansprüche an die Leistungsfähigkeit gerecht zu werden.
Background: Infections with the hepatitis C virus (HCV) are a global public health problem. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Newly introduced direct acting antivirals, especially interferon-free regimens, have improved rates of sustained viral response above 90% in most patient groups and allow treating patients who were ineligible for treatment in the past. These new regimens have replaced former treatment and are recommended by current guidelines. However, there is an ongoing discussion on high pharmaceutical prices. Our aim was to assess the long-term cost-effectiveness of treating hepatitis C genotype 1 patients with sofosbuvir/ledipasvir (SOF/LDV) treatment in Germany.
Material and Methods: We used a Markov cohort model to simulate disease progression and assess cost-effectiveness. The model calculates lifetime costs and outcomes (quality-adjusted life years, QALYs) of SOF/LDV and other strategies. Patients were stratified by treatment status (treatment-naive and treatment-experienced) and absence/presence of cirrhosis. Different treatment strategies were compared to prior standard of care. Sensitivity analyses were performed to evaluate model robustness.
Results: Base-case analyses results show that in treatment-naive non-cirrhotic patients treatment with SOF/LDV dominates the prior standard of care (is more effective and less costly). In cirrhotic patients an incremental cost-effectiveness ratio (ICER) of 3,383 €/QALY was estimated. In treatment-experienced patients ICERs were 26,426 €/QALY and 1,397 €/QALY for treatment-naive and treatment-experienced patients, respectively. Robustness of results was confirmed in sensitivity analyses.
Conclusions: Our analysis shows that treatment with SOF/LDV is cost-effective compared to prior standard of care in all patient groups considering international costs per QALY thresholds.
Tumor cells frequently overexpress heat shock protein 70 (Hsp70) and present it on their cell surface, where it can be recognized by pre‐activated NK cells. In our retrospective study the expression of Hsp70 was determined in relation to tumor‐infiltrating CD56+ NK cells in formalin‐fixed paraffin embedded (FFPE) tumor specimens of patients with SCCHN (N = 145) as potential indicators for survival and disease recurrence. All patients received radical surgery and postoperative cisplatin‐based radiochemotherapy (RCT). In general, Hsp70 expression was stronger, but with variable intensities, in tumor compared to normal tissues. Patients with high Hsp70 expressing tumors (scores 3–4) showed significantly decreased overall survival (OS; p = 0.008), local progression‐free survival (LPFS; p = 0.034) and distant metastases‐free survival (DMFS; p = 0.044), compared to those with low Hsp70 expression (scores 0–2), which remained significant after adjustment for relevant prognostic variables. The adverse prognostic value of a high Hsp70 expression for OS was also observed in patient cohorts with p16‐ (p = 0.001), p53‐ (p = 0.0003) and HPV16 DNA‐negative (p = 0.001) tumors. The absence or low numbers of tumor‐infiltrating CD56+ NK cells also correlated with significantly decreased OS (p = 0.0001), LPFS (p = 0.0009) and DMFS (p = 0.0001). A high Hsp70 expression and low numbers of tumor‐infiltrating NK cells have the highest negative predictive value (p = 0.00004). In summary, a strong Hsp70 expression and low numbers of tumor‐infiltrating NK cells correlate with unfavorable outcome following surgery and RCT in patients with SCCHN, and thus serve as negative prognostic markers.
We are pleased to introduce the sixth Journal Club. This edition is focused on several relevant studies published in the last years in the field of Strength and Conditioning, chosen by our Editorial Board members and their colleagues. We hope to stimulate your curiosity in this field and to share with you the passion for sport and exercise seen from a scientific point of view. The Editorial Board members wish you an inspiring read.
Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis
(2017)
Background: Refractory ascites (RA) is a frequent complication of cirrhosis, requiring large volume paracentesis or placement of a transjugular intrahepatic portosystemic shunt (TIPSS). The automated low-flow ascites pump (alfapump, Sequana Medical AG, Zurich, Switzerland) is an innovative treatment option for patients with RA.
Aim: To assess safety and efficacy of this treatment in patients with a contraindication to TIPSS.
Methods: Fifty-six patients (43 males; mean age 62 years) from centres in Germany, Switzerland, UK and Spain were included and followed for up to 24 months. Complications, device deficiencies, paracentesis frequency and patient survival were recorded.
Results: At the time of this analysis, 3 patients completed the 24-month observation period, monitoring of 3 was ongoing, 9 underwent liver transplantation, 17 patients were withdrawn due to serious adverse events and 23 patients died. Most frequently observed technical complication was blocking of the peritoneal catheter. Twenty-three pump-related reinterventions (17 patients) and 12 pump exchanges (11 patients) were required during follow-up. The pump system was explanted in 48% of patients (in 17 patients due to serious adverse events, in 9 at the time of liver transplantation and in 1 due to recovery from RA). Median frequency of paracentesis dropped from 2.17 to 0.17 per month.
Conclusions: The alfapump can expand therapeutic options for cirrhotic patients with RA. Continuous drainage of ascites in a closed loop automated system led to significant reduction in paracentesis frequency. Technical and procedural improvements are required to reduce the rate of adverse events and reinterventions.
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
(2017)
Background: In multiple sclerosis, coagulation factors have been shown to modulate inflammation. In this translational study, we investigated whether long-term anticoagulation with warfarin or rivaroxaban has beneficial effects on the course of autoimmune experimental encephalomyelitis (EAE).
Methods: Female SJL/J mice treated with anticoagulants namely warfarin or rivaroxaban were immunized with PLP139–151. Stable anticoagulation was maintained throughout the entire experiment. Mice without anticoagulation treated with the vehicle only were used as controls. The neurological deficit was recorded during the course of EAE, and histopathological analyses of inflammatory lesions were performed.
Results: In preventive settings, both treatment with warfarin and rivaroxaban reduced the maximum EAE score as compared to the control group and led to a reduction of inflammatory lesions in the spinal cord. In contrast, therapeutic treatment with warfarin had no beneficial effects on the clinical course of EAE. Signs of intraparenchymal hemorrhage at the site of the inflammatory lesions were not observed.
Conclusion: We developed long-term anticoagulation models that allowed exploring the course of EAE under warfarin and rivaroxaban treatment. We found a mild preventive effect of both warfarin and rivaroxaban on neurological deficits and local inflammation, indicating a modulation of the disease induction by anticoagulation.
Nutrition support is a necessary therapy for critically ill cardiac surgery patients. However, conclusive evidence for this population, consisting of well-conducted clinical trials is lacking. To clarify optimal strategies to improve outcomes, an international multidisciplinary group of 25 experts from different clinical specialties from Germany, Canada, Greece, USA and Russia discussed potential approaches to identify patients who may benefit from nutrition support, when best to initiate nutrition support, and the potential use of pharmaco-nutrition to modulate the inflammatory response to cardiopulmonary bypass. Despite conspicuous knowledge and evidence gaps, a rational nutritional support therapy is presented to benefit patients undergoing cardiac surgery.
Gene trap mutagenesis is a powerful tool to create loss-of-function mutations in mice and other model organisms. Modifications of traditional gene trap cassettes, including addition of conditional features in the form of Flip-excision (FlEx) arrays to enable directional gene trap cassette inversions by Cre and Flpe site-specific recombinases, greatly enhanced their experimental potential. By taking advantage of these conditional gene trap cassettes, we developed a generic strategy for generating conditional mutations and validated this strategy in mice carrying a multipurpose allele of the Prdm16 transcription factor gene. We demonstrate that the gene trap insertion creates a null mutation replicating the Pierre Robin sequence-type cleft palate phenotype of other Prdm16 mutant mice. Consecutive breeding to Flpe and Emx1IREScre deleter mice spatially restricted Prdm16 loss to regions of the forebrain expressing the homeobox gene Emx1, demonstrating the utility of the technology for the analysis of tissue-specific gene functions.